Research programme: cancer gene therapies - BioCancell

Drug Profile

Research programme: cancer gene therapies - BioCancell

Alternative Names: BC-820; BC-821; BC-822; H19-DTA+TNF; IGF2-DTA

Latest Information Update: 10 Nov 2015

Price : $50

At a glance

  • Originator BioCancell Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Nov 2015 BioCancell cover patents for BC 821 in USA, Japan, Europe, Russia, China, Australia and South Korea
  • 15 May 2012 Preclinical development is ongoing in Israel
  • 30 Dec 2010 BC 821 completes preclinical testing in Glioblastoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top